Seeking Alpha

Amgen (AMGN) says the FDA has approved a new indication for Prolia as a treatment to increase...

Amgen (AMGN) says the FDA has approved a new indication for Prolia as a treatment to increase bone mass in men with osteoporosis at high risk for fracture. Prolia is the first FDA-approved subcutaneous injection administered every six months. Studies of men with low bone mineral density who took the treatment resulted in significantly greater bone density gains when compared to a placebo.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector